Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
AstraZeneca’s Calquence Receives Conditional Approval in China for MCL
AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received conditional market approval in China...
Biohaven Acquires Global Rights for Dual TYK2/JAK1 Inhibitor BHV-8000 from Highlightll
US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions,...
Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA)...
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase...
Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD...
Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year...
Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...
JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial...
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December...
Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’...
Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...
Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Smith & Nephew Partners with MedMotion for Digital Health Innovation
UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...